Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 15/20 | 0.61 |
| ▸ | MMP9 | P14780 | 13/20 | 0.61 |
| ▸ | MMP8 | P22894 | 10/20 | 0.61 |
| ▸ | MMP1 | P03956 | 10/20 | 0.57 |
| ▸ | MMP3 | P08254 | 9/20 | 0.57 |
| ▸ | MMP13 | P45452 | 4/20 | 0.57 |
| ▸ | MMP14 | P50281 | 3/20 | 0.57 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.57 |
| ▸ | MMP7 | P09237 | 5/20 | 0.49 |
| ▸ | FCER2 | P06734 | 2/20 | 0.49 |
| ▸ | MMP12 | P39900 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6856648 | 0.85 | MME (0.56) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL8872686 | 0.84 | MMP2 (0.76) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL7997851 | 0.81 | USP2 (0.44) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL8601655 | 0.81 | MMP2 (0.65) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL20793033 | 0.81 | BIRC2 (0.57) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL9284706 | 0.75 | MMP9 (0.70) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL8269110 | 0.73 | MME (0.61) | MMP2MMP9MMP8MMP1MMP3 | |
| Ro-319790 SCHEMBL31060724 | 0.73 | MMP1 (1.00) | MMP2MMP9MMP8MMP1MMP3 | |
| Ro-319790 SCHEMBL8188276 | 0.73 | MMP1 (1.00) | MMP2MMP9MMP8MMP1MMP3 | |
| Ro-319790 SCHEMBL5494052 | 0.73 | MMP1 (1.00) | MMP2MMP9MMP8MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2282719-B1 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | REVALESIO CORP (US) | 2018-05-30 | — | — | EP | disclosed |